Short NJ, Rytting ME, Cortes JE (2018) Acute myeloid leukaemia. Lancet 392:593–606

Article  PubMed  PubMed Central  Google Scholar 

Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N et al (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: The JALSGAML201 study. Blood 117:2358–2365

Article  CAS  PubMed  Google Scholar 

DiNardo CD, Erba HP, Freeman SD, Wei AH (2023) Acute myeloid leukaemia. Lancet 401:2073–2086

Article  CAS  PubMed  Google Scholar 

Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127:53–61

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK et al (2018) CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol 36:2684–2692

Article  CAS  PubMed  PubMed Central  Google Scholar 

DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383:617–629

Article  CAS  PubMed  Google Scholar 

DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791–803

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maiti A, Rausch CR, Cortes JE, Pemmaraju N, Daver NG, Ravandi F et al (2021) Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimens. Haematologica 106:894–898

Article  PubMed  Google Scholar 

Matthews AH, Perl AE, Luger SM, Loren AW, Gill SI, Porter DL et al (2022) Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv 6:3997–4005

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338–350

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N et al (2015) Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): A randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncol 16:1025–1036

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hawtin RE, Stockett DE, Byl JAW, McDowell RS, Tan N, Arkin MR et al (2010) Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II. PLoS ONE 5:1–10

Article  Google Scholar 

Kazamori D, Aoi H, Sugimoto K, Ueshima T, Amano H, Itoh K et al (2014) In vitro activity of WQ-3810, a novel fluoroquinolone, against multidrug-resistant and fluoroquinolone-resistant pathogens. Int J Antimicrob Agents 44:443–449

Article  CAS  PubMed  Google Scholar 

Itoh K, Kuramoto Y, Amano H, Kazamori D, Yazaki A (2015) Discovery of WQ-3810: Design, synthesis, and evaluation of 7-(3-alkylaminoazetidin-1-yl)fluoro-quinolones as orally active antibacterial agents. Eur J Med Chem 103:354–360

Article  CAS  PubMed  Google Scholar 

Hirano T, Kinoshita T, Kazamori D, Inoue S, Nishimura K, Sakurai A et al (2018) Discovery of a Novel Fluoroquinolone Antibiotic Candidate WFQ-228 with Potent Antimicrobial Activity and the Potential to Overcome Major Drug Resistance. Chem Pharm Bull (Tokyo) 66:235–238

Article  CAS  PubMed  Google Scholar 

Giuliani F, Casazza AM, Di Marco A, Savi G (1981) Studies in mice treated with ICRF-159 combined with daunorubicin or doxorubicin. Cancer Treat Rep 65

Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Farahani MV, Hushmandi K et al (2022) Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects. Drug Discov Today 27:436–455

Article  CAS  PubMed  Google Scholar 

Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF et al (2012) Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 18:1639–1642

Article  PubMed  Google Scholar 

Jamieson GC, Fox JA, Poi M, Strickland SA (2016) Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia. Drugs 76:1245–1255

Article  CAS  PubMed  PubMed Central  Google Scholar 

Poulsen KL, Olivero-Verbel J, Beggs KM, Ganey PE, Roth RA (2014) Trovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response. J Pharmacol Exp Ther 350:164–170

Article  PubMed  PubMed Central  Google Scholar 

Kullenberg F, Peters K, Luna-Marco C, Salomonsson A, Kopsida M, Degerstedt O et al (2023) The progression of doxorubicin-induced intestinal mucositis in rats. Naunyn Schmiedebergs Arch Pharmacol 396:247–260

Article  CAS  PubMed  Google Scholar 

Hills RK, Castaigne S, Appelbaum FR, Delaunay J, Petersdorf S, Othus M et al (2014) Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986–996

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD et al (2017) Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med 377:454–464

Article  CAS  PubMed  PubMed Central  Google Scholar 

Erba HP, Montesinos P, Kim H-J, Patkowska E, Vrhovac R, Žák P et al (2023) Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1571–1583

Article  CAS  PubMed  Google Scholar 

Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H et al (2020) Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. N Engl J Med 383:2526–2537

Article  CAS  PubMed  Google Scholar 

Kim N, Norsworthy KJ, Subramaniam S, Chen H, Manning ML, Kitabi E et al (2022) FDA Approval Summary: Decitabine and Cedazuridine Tablets for Myelodysplastic Syndromes. Clin Cancer Res 28:3411–3416

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lim B, Yoo D, Chun Y, Go A, Cho KJ, Choi D et al (2022) The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia. Blood Cancer J 12

Ureshino H, Kurahashi Y, Watanabe T, Yamashita S, Kamachi K, Yamamoto Y et al (2021) Silylation of Deoxynucleotide Analog Yields an Orally Available Drug with Antileukemia Effects. Mol Cancer Ther 20:1412–1421

Article  CAS  PubMed  PubMed Central  Google Scholar